Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab with Chemoradiotherapy in Anal Canal Cancer
NCT01843452Phase 2Terminated
- Sponsor
- Lausanne University Hospital
- Start
- Dec 2012
- Primary completion
- May 2016
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of panitumumab in anal canal squamous cell carcinoma (SCCA), sponsored by Lausanne University Hospital. Started Dec 2012; status: terminated.
02
Drugs
panitumumab
03
Conditions
anal canal squamous cell carcinoma (SCCA)
Beyond the preview
Go deeper on NCT01843452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01843452.